Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero

AIDS

Volumn 26, Issue 16, 2012, Pages 2053-2058

  Cade, W Todd ^a   Waggoner, Alan D ^a   Hubert, Sara ^a   Krauss, Melissa J ^a   Singh, Gautam K ^a   Overton, E Turner ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

antiretroviral therapy; children; diastolic; heart; in utero

Indexed keywords

COCAINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ARTICLE; CHILD; COCAINE DEPENDENCE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EXPOSURE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; PRENATAL EXPOSURE; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SYSTOLIC DYSFUNCTION;

ANTI-HIV AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MATERNAL AGE; MYOCARDIAL CONTRACTION; ORGAN SIZE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; SUBSTANCE-RELATED DISORDERS; VENTRICULAR FUNCTION, LEFT;

EID: 84867744322     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328358d4d7     Document Type: Article

References (35)

1. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998; 97:1246-1256.
2. Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003; 41:1598-1605.
3. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pedia-tric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 2000; 102:1542-1548.
4. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet 2002; 360:368-373.
5. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 2011; 57:76-85.
6. Zareba KM, Lavigne JE, Lipshultz SE. Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol 2004; 4:271-279.
7. Stevens SM, Farzaneh-Far R, Na B, Whooley MA, Schiller NB. Development of an echocardiographic risk-stratification index to predict heart failure in patients with stable coronary artery disease: the Heart and Soul study. JACC Cardiovasc Imaging 2009; 2:11-20.
8. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 2004; 148:883-888.
9. Starc TJ, Lipshultz SE, Easley KA, Kaplan S, Bricker JT, Colan SD, et al. Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study. J Pediatr 2002; 141:327-334.
10. McMahon CJ, Nagueh SF, Eapen RS, Dreyer WJ, Finkelshtyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart 2004; 90:908-915.
11. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
12. Eidem BW, McMahon CJ, Cohen RR, Wu J, Finkelshteyn I, Kovalchin JP, et al. Impact of cardiac growth on Doppler tissue imaging velocities: a study in healthy children. J Am Soc Echocardiogr 2004; 17:212-221.
13. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107-133.
14. Cade W, Holland MR, Stephens AS, Reeds DN, Laciny DN, Cilbulka N, et al. Decreased myocardial longitudinal strain in HIV-negative neonates exposed to HIV and HAART in utero (abstract). Antiviral Therapy 2009; 14 Suppl 2:A13.
15. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluationof left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474-480.
16. Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active anti-retroviral therapy. Clin Infect Dis 2011; 52:378-386.
17. Reinsch N, Kahlert P, Esser S, Sundermeyer A, Neuhaus K, Brockmeyer N, et al. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis 2011; 1:176-184.
18. Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3:132-139.
19. Schuster I, Thoni GJ, Ederhy S, Walther G, Nottin S, Vinet A, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213-1217.
20. Oliviero U, Bonadies G, Bosso G, Foggia M, Apuzzi V, Cotugno M, et al. Impaired diastolic function in naive untreated human immunodeficiency virus infected patients. World J Cardiol 2010; 2:98-103.
21. Kelly K, Tarwater P, Karper J, Bedja D, Queen S, Tunin R, et al. Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS 2012; 26:815-823.
22. Chang WT, Wu CC, Hung CC, Chen MY, Fang CT, Chen WJ, et al. Left ventricular dysfunction is associated with CD4 lymphocyte count rather than opportunistic infection in human immunodeficiency virus infection. J Formos Med Assoc 2003; 102:158-163.
23. Longo-Mbenza B, Seghers LV, Vita EK, Tonduangu K, Bayekula M. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 1998; 80:184-189.
24. Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Davila-Roman VG, et al. Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. Cardiovasc Diabetol 2011; 10:111.
25. Barker DJ. Fetal origins of coronary heart disease. BMJ 1995; 311:171-174.
26. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee S, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr 2002; 30:306-310.
27. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group. N Engl J Med 2000; 343:759-766.
28. Lewis W, Papoian T. Molecular mechanisms of heart muscle disease. West J Med 1991; 154:91.
29. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne RM, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991; 65:228-236.
30. Gerschenson M, Poirier MC. Fetal patas monkeys sustain mi-tochondrial toxicity as a result of in utero zidovudine exposure. Ann N Y Acad Sci 2000; 918:269-281.
31. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508-510.
32. Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 2009; 54:36-46.
33. Torres SM, March TH, Carter MM, McCash CL, Seilkop SK, Poirier MC, et al. In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue. Cardiovasc Toxicol 2010; 10:37-50.
34. Bishop JB, Tani Y, Witt K, Johnson JA, Peddada S, Dunnick J, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004; 81:512-517.
35. McGrath CJ NR, Richardson BA, Kristal AR, Mbori-Ngacha D, Farquhar C, John-Stewart GC. The Prevalence of stunting is high in HIV-1-exposed uninfected infants in Kenya. J Nutr 2012; 142:757-763.